Here are the drugs that have been delayed:
PALFORZIA
Aimmune Therapeutics Inc paused the launch of the first peanut
allergy treatment to be approved by U.S. regulators until later this
year because of the widespread closure of allergists' practices. It
is the company's only approved product, meaning Aimmune is unlikely
to make the $48 million in annual revenue some analysts had
previously projected.
ONGENTYS
Neurocrine Biosciences Inc has delayed the launch of its Parkinson's
treatment, which analysts expected to generate nearly $9 million in
its first year, until later this year, in part because it said
neurologists had been busy helping treat COVID-19 patients.
XIAFLEX
Endo International PLC has delayed the launch of its drug Xiaflex as
a cellulose treatment until later in 2020, even though the FDA is
due to give a formal verdict on its approval in July. Xiaflex earned
$89 million in the first quarter of 2020 for use in other
conditions, such as painful erections. Endo executives told Reuters
they expect to see a surge of patients starting new prescription
drugs once social distancing measures lift.
[to top of second column] |
SARCLISA
Sanofi SA launched its multiple myeloma treatment, Sarclisa, in March, but then
paused the ramp up and delayed full commercialization until the COVID-19
pandemic subsides. Analysts projected the drug would earn $173 million in its
first year.
ZEPOSIA
This treatment for relapsing multiple sclerosis was approved late March and was
expected by some analysts to earn as much as $91 million in 2020. Bristol Myers
Squibb Co delayed the product, citing a slowdown in new drug starts in the early
days of the pandemic, but it moved forward with the launch in June because
"physicians are beginning to actively initiate new therapies," said chief
commercial officer Christopher Boerner during a recent investor call.
(Reporting by Carl O'Donnell and Manas Mishra in Bengaluru; additional reporting
by Dania Nadeem in Bengaluru; Editing by Mark Potter)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |